The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Managing patients with difficult to treat multiple myeloma
In this video, Joshua Richter, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the management of patients with difficult to treat multiple myeloma, highlighting the importance of understanding functionally high-risk disease and evaluating additional genomic information in these patients. Dr Richter also comments on important novel agents to consider, such as belantamab mafodotin and selinexor. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Celgene/BMS, Secura Bio, Oncopeptides and Takeda; speakers bureau: Janssen, Sanofi and Adaptive Biotechnologies
Advisory Boards: Celgene/BMS, Janssen, Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura Bio and AstraZeneca
